{"doi":"10.21037/tlcr-20-331","title":"How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)","abstract":null,"journal":"Translational Lung Cancer Research","year":2020,"id":613682,"datarank":0.47670807455219194,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"self_citation_contribution":0.47670807455219194,"citation_network_contribution":0.0,"self_endowment_contribution":0.47670807455219194,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":441891,"name":"Misako Nagasaka","orcid":"0000-0001-5308-615X","position":1,"is_corresponding":false},{"id":305410,"name":"Viola W. Zhu","orcid":"0000-0002-9313-3253","position":2,"is_corresponding":false},{"id":1581094,"name":"Sai-Hong Ignatius Ou","orcid":null,"position":3,"is_corresponding":false},{"id":321564,"name":"Ross A. Soo","orcid":"0000-0002-3053-3997","position":4,"is_corresponding":false},{"id":444092,"name":"Bing Xia","orcid":"0000-0003-3259-6139","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)","abstract":"Abstract: Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor was approved. Since then, subsequent generations of ALK inhibitors have demonstrated superior efficacy and better CNS activity compared to crizotinib. Alectinib and brigatinib, both second-generation ALK inhibitors have been compared directly to crizotinib in the first-line setting and has demonstrated improved progression free survival (PFS) and intracranial response. Ceritinib, another second-generation ALK inhibitor has been shown to be superior to chemotherapy in ALK-rearranged disease with good CNS activity. Initial responses to ALK inhibitors are not always durable and resistance can occur as on-target or off-target alterations. Lorlatinib, a third-generation ALK inhibitor, has demonstrated activity in the treatment naïve setting and in resistance to crizotinib and second-generation ALK inhibitors. Lorlatinib has also shown improved PFS in patients harboring EML4-ALK variant 3, which is associated with the development of ALK resistance mutations, specifically G1202R. Another new ALK inhibitor, ensartinib, has demonstrated efficacy in the first-line setting and in alectinib refractory disease. Additional studies are underway examining mechanisms of resistance and best treatment options post resistance.","is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33489815","pmcid":"PMC7815371","openalex_id":"https://openalex.org/W3044516145","authors":[],"funders":[],"total_grants":0,"fwci":1.645,"citation_percentile":0.86945276,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":7},{"year":2023,"count":5},{"year":2024,"count":6},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://tlcr.amegroups.com/article/viewFile/41998/pdf","host_type":"journal"},{"url":"https://tlcr.amegroups.com/article/viewFile/41998/pdf","host_type":"publisher"},{"url":"http://tlcr.amegroups.com/article/download/41998/pdf","host_type":"publisher"},{"url":"https://doi.org/10.21037/tlcr-20-331","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33489815","host_type":"repository"},{"url":"https://escholarship.org/uc/item/4606t439","host_type":"repository"},{"url":"http://europepmc.org/pmc/articles/PMC7815371","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7815371","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7815371","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7815371?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Lung Cancer Research Studies","Cancer therapeutics and mechanisms"],"mesh_terms":[],"keywords":["Medicine","non-small cell lung cancer (NSCLC)","Oncology","Lung cancer","Disease","Targeted therapy","Internal medicine","Cancer research","Bioinformatics","Cancer","Biology","Anaplastic Lymphoma Kinase (Alk)","Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor (Alk Tkis)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T08:56:08.095447Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}